Israel Englander’s Telomir Pharmaceuticals TELO Stock Holding History

Israel Englander’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-129,060	Closed	-$168K	–	6486
2026 Q1	$168K	Sell	129,060 -37,915	-23%	-$48.4K	﹤0.01%	5231
2025 Q4	$222K	Sell	166,975 -55,429	-25%	-$80K	﹤0.01%	5422
2025 Q3	$309K	Sell	222,404 -25,295	-10%	-$38.1K	﹤0.01%	5326
2025 Q2	$310K	Buy	+247,699	New	+$573K	﹤0.01%	5177

Other funds holding TELO

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

WIA

World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Israel Englander's TELO Position: Q2 2026 in Review

Israel Englander sold out of Telomir Pharmaceuticals (TELO) in Q2 2026, closing a stake of 129,060 shares — an estimated $168K sold.

Israel Englander first reported a position in TELO in Q2 2025 and held it in 4 quarters. The position peaked at $310K in Q2 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

Israel Englander reported no remaining Telomir Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 129,060 Telomir Pharmaceuticals shares in Q2 2026, an estimated $168K.
Israel Englander first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Israel Englander's Telomir Pharmaceuticals position peaked at $310K in Q2 2025.
33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.